JP2014524735A - レチノイドｘレセプターの調節因子の活性を予測する方法および組成物 - Google Patents
レチノイドｘレセプターの調節因子の活性を予測する方法および組成物 Download PDFInfo
- Publication number
- JP2014524735A JP2014524735A JP2014514846A JP2014514846A JP2014524735A JP 2014524735 A JP2014524735 A JP 2014524735A JP 2014514846 A JP2014514846 A JP 2014514846A JP 2014514846 A JP2014514846 A JP 2014514846A JP 2014524735 A JP2014524735 A JP 2014524735A
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- complement
- snps
- group
- biomarkers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000034527 Retinoid X Receptors Human genes 0.000 title claims abstract description 34
- 108010038912 Retinoid X Receptors Proteins 0.000 title claims abstract description 34
- 230000000694 effects Effects 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title claims description 68
- 239000000203 mixture Substances 0.000 title description 7
- 229940075993 receptor modulator Drugs 0.000 title 1
- 239000000090 biomarker Substances 0.000 claims abstract description 102
- 238000011282 treatment Methods 0.000 claims abstract description 101
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 claims abstract description 60
- 229960002938 bexarotene Drugs 0.000 claims abstract description 58
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 29
- 201000010099 disease Diseases 0.000 claims abstract description 24
- 238000002405 diagnostic procedure Methods 0.000 claims abstract description 23
- 230000002411 adverse Effects 0.000 claims abstract description 13
- 230000008901 benefit Effects 0.000 claims abstract description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 55
- 239000002773 nucleotide Substances 0.000 claims description 49
- 230000000295 complement effect Effects 0.000 claims description 29
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- 238000004458 analytical method Methods 0.000 claims description 21
- 108020004414 DNA Proteins 0.000 claims description 20
- 238000002493 microarray Methods 0.000 claims description 20
- 239000003153 chemical reaction reagent Substances 0.000 claims description 18
- 230000004043 responsiveness Effects 0.000 claims description 18
- 108091034117 Oligonucleotide Proteins 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 16
- 102000040430 polynucleotide Human genes 0.000 claims description 16
- 108091033319 polynucleotide Proteins 0.000 claims description 16
- 239000002157 polynucleotide Substances 0.000 claims description 16
- 238000003556 assay Methods 0.000 claims description 13
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 11
- 239000000758 substrate Substances 0.000 claims description 10
- 239000003613 bile acid Substances 0.000 claims description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 8
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 8
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 8
- 238000004422 calculation algorithm Methods 0.000 claims description 8
- 102000004311 liver X receptors Human genes 0.000 claims description 8
- 108090000865 liver X receptors Proteins 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 102100038495 Bile acid receptor Human genes 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 claims description 7
- 230000008236 biological pathway Effects 0.000 claims description 7
- 102000003702 retinoic acid receptors Human genes 0.000 claims description 7
- 108090000064 retinoic acid receptors Proteins 0.000 claims description 7
- 102000007469 Actins Human genes 0.000 claims description 6
- 108010085238 Actins Proteins 0.000 claims description 6
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 6
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 6
- 239000003596 drug target Substances 0.000 claims description 6
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 6
- 238000012163 sequencing technique Methods 0.000 claims description 6
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 5
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 5
- 238000009396 hybridization Methods 0.000 claims description 5
- 201000005962 mycosis fungoides Diseases 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 5
- 230000009103 reabsorption Effects 0.000 claims description 5
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 4
- 238000005251 capillar electrophoresis Methods 0.000 claims description 4
- 238000000840 electrochemical analysis Methods 0.000 claims description 4
- 238000001502 gel electrophoresis Methods 0.000 claims description 4
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 4
- 238000004949 mass spectrometry Methods 0.000 claims description 4
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 210000004292 cytoskeleton Anatomy 0.000 claims description 3
- 102000006495 integrins Human genes 0.000 claims description 3
- 108010044426 integrins Proteins 0.000 claims description 3
- 102000009855 Inwardly Rectifying Potassium Channels Human genes 0.000 claims description 2
- 108010009983 Inwardly Rectifying Potassium Channels Proteins 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- 230000033228 biological regulation Effects 0.000 claims description 2
- 230000030648 nucleus localization Effects 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 238000011285 therapeutic regimen Methods 0.000 claims description 2
- 208000017144 Metabolic Skin disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 40
- 229940079593 drug Drugs 0.000 abstract description 30
- 230000004044 response Effects 0.000 abstract description 27
- 230000001225 therapeutic effect Effects 0.000 abstract description 20
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract description 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 57
- 108090000623 proteins and genes Proteins 0.000 description 42
- 239000000523 sample Substances 0.000 description 39
- 108700028369 Alleles Proteins 0.000 description 36
- 102100035182 Plastin-2 Human genes 0.000 description 32
- 229930012538 Paclitaxel Natural products 0.000 description 31
- 229960001592 paclitaxel Drugs 0.000 description 31
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 31
- 101000596046 Homo sapiens Plastin-2 Proteins 0.000 description 28
- 101000762938 Homo sapiens TOX high mobility group box family member 4 Proteins 0.000 description 28
- 230000002974 pharmacogenomic effect Effects 0.000 description 27
- 150000007523 nucleic acids Chemical class 0.000 description 25
- 102000039446 nucleic acids Human genes 0.000 description 24
- 108020004707 nucleic acids Proteins 0.000 description 24
- 238000011269 treatment regimen Methods 0.000 description 24
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 22
- 238000003205 genotyping method Methods 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 16
- 230000004083 survival effect Effects 0.000 description 14
- 102100021711 Ileal sodium/bile acid cotransporter Human genes 0.000 description 13
- 108091006614 SLC10A2 Proteins 0.000 description 13
- 208000006575 hypertriglyceridemia Diseases 0.000 description 13
- 210000002381 plasma Anatomy 0.000 description 12
- 239000000556 agonist Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 8
- 208000017520 skin disease Diseases 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- 210000000349 chromosome Anatomy 0.000 description 7
- 239000000306 component Substances 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 102000006255 nuclear receptors Human genes 0.000 description 7
- 108020004017 nuclear receptors Proteins 0.000 description 7
- 201000003883 Cystic fibrosis Diseases 0.000 description 6
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 6
- 108010016731 PPAR gamma Proteins 0.000 description 6
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 108010049148 plastin Proteins 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 108010000178 IGF-I-IGFBP-3 complex Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000003321 amplification Effects 0.000 description 4
- 238000012098 association analyses Methods 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 229940104302 cytosine Drugs 0.000 description 4
- 208000037765 diseases and disorders Diseases 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- -1 ribose sugars Chemical class 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101000987488 Homo sapiens Protein pelota homolog Proteins 0.000 description 3
- 102100025323 Integrin alpha-1 Human genes 0.000 description 3
- 102100028485 Protein pelota homolog Human genes 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 239000003114 blood coagulation factor Substances 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 102000054766 genetic haplotypes Human genes 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 102100040750 CUB and sushi domain-containing protein 1 Human genes 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000003847 Carboxypeptidase B2 Human genes 0.000 description 2
- 102100035023 Carboxypeptidase B2 Human genes 0.000 description 2
- 108090000201 Carboxypeptidase B2 Proteins 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 230000033616 DNA repair Effects 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 101000892017 Homo sapiens CUB and sushi domain-containing protein 1 Proteins 0.000 description 2
- 101000946518 Homo sapiens Carboxypeptidase B2 Proteins 0.000 description 2
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 102000002151 Microfilament Proteins Human genes 0.000 description 2
- 102000023984 PPAR alpha Human genes 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 206010066901 Treatment failure Diseases 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 108091000387 actin binding proteins Proteins 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000004709 cell invasion Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940121657 clinical drug Drugs 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000009699 differential effect Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 238000010230 functional analysis Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000003632 microfilament Anatomy 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 2
- 229930192033 plastin Natural products 0.000 description 2
- 230000004983 pleiotropic effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 229940099419 targretin Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 238000010173 Alzheimer-disease mouse model Methods 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014486 Elevated triglycerides Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 101001071240 Homo sapiens PHD finger protein 13 Proteins 0.000 description 1
- 101000613350 Homo sapiens Polycomb group RING finger protein 5 Proteins 0.000 description 1
- 101000738388 Homo sapiens Uncharacterized protein C4orf50 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 108010041341 Integrin alpha1 Proteins 0.000 description 1
- 206010027236 Meningitis fungal Diseases 0.000 description 1
- 206010027260 Meningitis viral Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102100036867 PHD finger protein 13 Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 102100040916 Polycomb group RING finger protein 5 Human genes 0.000 description 1
- 102000012425 Polycomb-Group Proteins Human genes 0.000 description 1
- 108010022429 Polycomb-Group Proteins Proteins 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102100033390 Testican-1 Human genes 0.000 description 1
- 101710144222 Testican-1 Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 102100037900 Uncharacterized protein C4orf50 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000027137 acute motor axonal neuropathy Diseases 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
- 229940059260 amidate Drugs 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 102000043871 biotin binding protein Human genes 0.000 description 1
- 108700021042 biotin binding protein Proteins 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 201000010056 fungal meningitis Diseases 0.000 description 1
- 150000002243 furanoses Chemical class 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 150000003215 pyranoses Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008791 toxic response Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 201000010044 viral meningitis Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/30—Prediction of properties of chemical compounds, compositions or mixtures
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Primary Health Care (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161494773P | 2011-06-08 | 2011-06-08 | |
| US61/494,773 | 2011-06-08 | ||
| PCT/US2012/041379 WO2012170704A2 (en) | 2011-06-08 | 2012-06-07 | Methods and compositions of predicting activity of retinoid x receptor modulator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014524735A true JP2014524735A (ja) | 2014-09-25 |
| JP2014524735A5 JP2014524735A5 (cg-RX-API-DMAC7.html) | 2015-07-23 |
Family
ID=47296742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014514846A Pending JP2014524735A (ja) | 2011-06-08 | 2012-06-07 | レチノイドｘレセプターの調節因子の活性を予測する方法および組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10202652B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2718486A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2014524735A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140039278A (cg-RX-API-DMAC7.html) |
| CN (1) | CN103649386B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012267877B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013031221A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2838207A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2013014437A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2013158861A (cg-RX-API-DMAC7.html) |
| SG (1) | SG195191A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012170704A2 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019044852A1 (ja) * | 2017-08-31 | 2019-03-07 | 株式会社資生堂 | レチノイドの副作用に対する感受性の決定方法 |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2726511T (lt) | 2011-07-01 | 2019-11-11 | Ngm Biopharmaceuticals Inc | Kompozicijos, panaudojimai ir būdai, skirti metabolinių sutrikimų ir ligų gydymui |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| AU2013352363B2 (en) | 2012-11-28 | 2018-04-12 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| AU2013370404B2 (en) | 2012-12-27 | 2017-11-02 | Ngm Biopharmaceuticals, Inc. | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| US11089959B2 (en) * | 2013-03-15 | 2021-08-17 | I2Dx, Inc. | Electronic delivery of information in personalized medicine |
| US9782075B2 (en) * | 2013-03-15 | 2017-10-10 | I2Dx, Inc. | Electronic delivery of information in personalized medicine |
| MX377380B (es) | 2013-10-28 | 2025-03-10 | Ngm Biopharmaceuticals Inc | Modelos de cáncer y métodos asociados. |
| US20150147339A1 (en) * | 2013-11-15 | 2015-05-28 | Psma Development Company, Llc | Biomarkers for psma targeted therapy for prostate cancer |
| SI3097122T1 (sl) | 2014-01-24 | 2020-07-31 | Ngm Biopharmaceuticals, Inc. | Protitelesa, ki se vežejo v domeni beta klotho 2, in metode za njihovo uporabo |
| WO2015183890A2 (en) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders and diseases |
| EP3155005A4 (en) | 2014-06-16 | 2018-07-11 | NGM Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| CN104131102B (zh) * | 2014-08-07 | 2016-06-15 | 马飞 | 一种判断nsclc患者对吉非替尼治疗反应性的试剂盒 |
| UA123763C2 (uk) | 2014-10-23 | 2021-06-02 | Енджіем Байофармасьютикалз, Інк. | Фармацевтична композиція для контролю або лікування захворювання або порушення, пов’язаного з fgf19 |
| US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| WO2017019957A2 (en) | 2015-07-29 | 2017-02-02 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
| CA3003616C (en) | 2015-11-09 | 2020-07-28 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
| CA3034399A1 (en) | 2016-08-26 | 2018-03-01 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
| JOP20190025A1 (ar) * | 2016-09-01 | 2019-02-19 | Denovo Biopharma Llc | طرق وتركيبة لتوقع نشاط إنزاستورين |
| CN108504733A (zh) * | 2017-11-29 | 2018-09-07 | 中山拓普基因科技有限公司 | 肿瘤个体化化疗用药指导基因snp位点检测组合物 |
| KR102169699B1 (ko) * | 2019-12-27 | 2020-10-23 | 주식회사 클리노믹스 | 유전자 검사를 위한 맞춤형 유전자칩 및 이의 제작 방법 |
| AU2021231683A1 (en) | 2020-03-06 | 2022-09-22 | Denovo Biopharma Llc | Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters |
| KR20250118433A (ko) * | 2024-01-30 | 2025-08-06 | 서울대학교산학협력단 | 알츠하이머병 발병 위험도 예측을 위한 레이 복잡도 복사 점수 저하와 관련이 있는 단일염기다형성 마커 및 이의 용도 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1931805A2 (en) * | 2005-09-30 | 2008-06-18 | Perlegen Sciences, Inc. | Methods and compositions for screening and treatment of disorders of blood glucose regulation |
| JP2009510114A (ja) * | 2005-09-30 | 2009-03-12 | ビテ ファーマシューティカルズ， インコーポレイテッド | 特定のｒｘｒアゴニストによる癌治療 |
| US20080299125A1 (en) | 2006-06-05 | 2008-12-04 | Perlegen Sciences, Inc. | Genetic basis of treatment response in depression patients |
| WO2009134774A1 (en) | 2008-04-28 | 2009-11-05 | Expression Analysis | Methods and systems for simultaneous allelic contrast and copy number association in genome-wide association studies |
| EP2451455A4 (en) | 2009-07-10 | 2013-01-16 | Univ Case Western Reserve | RXR AGONIST COMPOUNDS AND METHODS |
| CA2779223A1 (en) * | 2009-10-27 | 2011-05-12 | Caris Mpi, Inc. | Molecular profiling for personalized medicine |
| US7790396B1 (en) | 2009-12-23 | 2010-09-07 | Suregene, Llc | Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype |
-
2012
- 2012-06-07 KR KR1020147000545A patent/KR20140039278A/ko not_active Withdrawn
- 2012-06-07 MX MX2013014437A patent/MX2013014437A/es not_active Application Discontinuation
- 2012-06-07 WO PCT/US2012/041379 patent/WO2012170704A2/en not_active Ceased
- 2012-06-07 CN CN201280027212.8A patent/CN103649386B/zh not_active Expired - Fee Related
- 2012-06-07 SG SG2013087861A patent/SG195191A1/en unknown
- 2012-06-07 RU RU2013158861/10A patent/RU2013158861A/ru not_active Application Discontinuation
- 2012-06-07 US US14/124,668 patent/US10202652B2/en active Active
- 2012-06-07 JP JP2014514846A patent/JP2014524735A/ja active Pending
- 2012-06-07 EP EP12797326.1A patent/EP2718486A4/en not_active Ceased
- 2012-06-07 BR BR112013031221A patent/BR112013031221A2/pt not_active IP Right Cessation
- 2012-06-07 AU AU2012267877A patent/AU2012267877B2/en not_active Ceased
- 2012-06-07 CA CA2838207A patent/CA2838207A1/en not_active Abandoned
Non-Patent Citations (7)
| Title |
|---|
| ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, vol. Vol.21, JPN6016012351, 2001, pages 2039 - 2045 * |
| BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. Vol.341, JPN6016012347, 2006, pages 792 - 796 * |
| HUMAN GENETICS, vol. Vol.125, JPN6016012350, 2009, pages 381 - 391 * |
| JOURNAL OF CLINICAL ONCOLOGY, vol. 24, no. 30, JPN6016012348, 2006, pages 4848 - 4854 * |
| MOLECULAR PSYCHIATRY, vol. Vol.16, JPN6016012346, January 2011 (2011-01-01), pages 76 - 85 * |
| THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 301, no. 4, JPN7017000763, 2009, pages 393 - 403 * |
| THE ONCOLOGIST, vol. Vol.10, JPN6016012349, 2005, pages 22 - 33 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019044852A1 (ja) * | 2017-08-31 | 2019-03-07 | 株式会社資生堂 | レチノイドの副作用に対する感受性の決定方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2013158861A (ru) | 2015-07-20 |
| US10202652B2 (en) | 2019-02-12 |
| EP2718486A4 (en) | 2014-12-31 |
| WO2012170704A2 (en) | 2012-12-13 |
| KR20140039278A (ko) | 2014-04-01 |
| CN103649386B (zh) | 2015-12-23 |
| CA2838207A1 (en) | 2012-12-13 |
| EP2718486A2 (en) | 2014-04-16 |
| BR112013031221A2 (pt) | 2017-01-24 |
| AU2012267877B2 (en) | 2015-12-24 |
| MX2013014437A (es) | 2015-03-20 |
| CN103649386A (zh) | 2014-03-19 |
| WO2012170704A3 (en) | 2013-01-31 |
| AU2012267877A1 (en) | 2014-01-23 |
| SG195191A1 (en) | 2013-12-30 |
| US20150368720A1 (en) | 2015-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014524735A (ja) | レチノイドｘレセプターの調節因子の活性を予測する方法および組成物 | |
| US20210108266A1 (en) | Method for discovering pharmacogenomic biomarkers | |
| TWI771317B (zh) | 使用藥物基因體學標記的組合物及方法 | |
| US20230193388A1 (en) | Compositions and methods for assessing the efficacy of inhibitors of neurotranmitter transporters | |
| WO2015168252A1 (en) | Mitochondrial dna copy number as a predictor of frailty, cardiovascular disease, diabetes, and all-cause mortality | |
| CN108070659B (zh) | Snp标志物在预测tam辅助内分泌治疗乳腺癌患者疗效中的应用 | |
| KR20170049768A (ko) | 피부 색상 및 흑화 민감도 진단용 단일염기다형성 마커 및 이의 용도 | |
| KR101795920B1 (ko) | 폐암 환자의 생존 예측용 ｓｌｃ５ａ１０ 다형성 마커 및 이를 이용한 폐암 생존 예후의 예측 방법 | |
| JP2024534509A (ja) | ｃｆＲＮＡおよびｃｆＴＮＡの標的ＮＧＳシーケンシングのための組成物および方法 | |
| HK40083504A (en) | Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters | |
| HK1196399A (en) | Method for discovering pharmacogenomic biomarkers | |
| HK1196399B (en) | Method for discovering pharmacogenomic biomarkers | |
| JPWO2006068111A1 (ja) | ＰＰＡＲγ遺伝子の遺伝子多型に関連する表現型の判定方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150605 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150605 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160330 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160630 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160830 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160929 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170306 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170602 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170804 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180202 |